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Abstract
Introduction Enhanced recovery after surgery (ERAS) pathways have been proven to enhance postoperative
recovery, reduce morbidity, and reduce length of hospital stay after colorectal cancer surgery. However, despite the
benefits of the ERAS program on short-term results, little is known about its impact on long-term results.
Objective The aim of the study was to determine the association between adherence to the ERAS protocol and long-
term survival after laparoscopic colorectal resection for non-metastatic cancer.
Material and Methodology Between 2013 and 2016, 350 patients underwent laparoscopic colorectal cancer resection
in the 2nd Department of General Surgery, Jagiellonian University Medical College, and were enrolled for further
analysis. The relationship between the rate of compliance with the ERAS protocol and 3-year survival was analyzed
according to the Kaplan–Meier method with log-rank tests. Patients were divided into two groups according to their
degree of adherence to the ERAS interventions: Group 1 (109 patients),\ 80% adherence, and Group 2 (241
patients), C 80% adherence. The primary outcome was overall 3-year survival. The secondary outcomes were
postoperative complications, length of hospital stay, and recovery parameters.
Results The groups were similar in terms of demographics and surgical parameters. The median compliance to
ERAS interventions was 85.2%. The Cox proportional model showed that AJCC III (HR 3.28, 95% CI 1.61–6.59,
p = 0.0021), postoperative complications (HR 2.63, 95% CI 1.19–5.52, p = 0.0161), and compliance with ERAS
protocol\ 80% (HR 3.38, 95% CI 2.23–5.21, p = 0.0102) were independent predictors for poor prognosis. Addi-
tionally, analysis revealed that adherence to the ERAS protocol in Group 2 with C 80% adherence was associated
with a significantly shorter length of hospital stay (6 vs. 4 days, p\ 0.0001), a lower rate of postoperative com-
plications (44.7% vs. 23.3%, p\ 0.0001), and improved functional recovery parameters: tolerance of oral diet
(53.4% vs. 81.5%, p\ 0.0001) and mobilization (77.7% vs. 96.1%, p\ 0.0001) on the first postoperative day.
Conclusions and Relevance This study reports an association between adherence to the ERAS protocol and long-
term survival after laparoscopic colorectal resection for non-metastatic cancer. Lower adherence to the protocol,
independent from stage of cancer and postoperative complications, was an independent risk factors for poorer
survival rates.
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Introduction
Many studies have shown that the enhanced recovery after
surgery (ERAS) protocol accelerates convalescence, redu-
ces complications, and shortens hospital stay after col-
orectal cancer surgery [1–3]. It also reduces the rate of
complications and delayed recovery in patients with tra-
ditional risk factors (demographic parameters and stage of
the disease) [4, 5]. Other research has reported that pro-
longed hospital stay and complications are associated with
a lower level of compliance with some ERAS protocol
elements that are mostly under the control of the care giver,
such as fluid balance, preoperative carbohydrate loading, or
surgical technique [6–9]. The use of catheters, drains, and
obviously the development of postoperative complications
also prolong hospital stay. Several previous studies have
shown that compliance with the ERAS protocol is strongly
correlated with short-term outcomes, such as postoperative
complications, readmission rate, and shortened length of
hospital stay [10–13]. An increase in compliance to the
ERAS protocol from high to very high/complete has also
been associated with further improvement in short-term
outcomes [14]. This is important because large data suggest
that postoperative complications may not only have an
impact in the short term, but may also affect long-term life
expectancy [15]. Two published studies, one in elective
orthopedic surgery and another following elective open
colorectal cancer surgery, reported that the introduction of
ERAS principles was associated with improved long-term
survival [11, 16]. The reasons for this association is
unknown. The aim of this study was to analyze whether the
level of adherence with the ERAS protocol had any impact
on long-term survival after laparoscopic colorectal resec-
tion for cancer.
Material and methods
A prospective observation was undertaken with post hoc
analysis of consecutive colorectal cancer patients operated
between 2013 and 2016. ERAS protocol was introduced in
2013 as a standard protocol for perioperative care in our
department. Each patient is initially planned for laparo-
scopy, and an open-surgery approach is performed mainly
in the case of conversion or when an extended multivis-
ceral resection is required. Follow-up was conducted based
on oncology visits, imaging studies, and CEA measure-
ments carried out in accordance with recent oncological
guidelines. Follow-up controls are carried out every
3–6 months for the first 2 years, and thereafter every
6 months for the next 3 years according to European
society for medical oncology (ESMO) guidelines [17]. The
exact date of death of patients who passed away was
established using information from the national personal
identification number database (PESEL).
Inclusion and exclusion criteria
Inclusion criteria were age over 18 years, histopathologi-
cally confirmed adenocarcinoma of colon or rectum, initial
laparoscopic approach, and patients with at least 12 months
of follow-up. Exclusion criteria were emergency or initially
open surgery, transanal endoscopic microsurgery (TEM),
concomitant inflammatory bowel diseases, and patients
with stage IV cancer according to the AJCC classification.
Figure 1 shows the patients’ flow through the study. In all
patients, the 16-item ERAS protocol was applied (Table 1).
Mean compliance with ERAS protocol elements in entire
group was 85.2%.
Operative technique
Following anesthesia, patients were placed in the low
lithotomy position. After creating pneumoperitoneum
(12 mm Hg), 4–6 trocars (5–12 mm) were inserted
depending on the type of resection. A standard 10-mm 300
laparoscope camera was used together with a set of Olympus
laparoscopic hand instruments. The procedure consisted of
medial-to-lateral laparoscopic mobilization of the segment
of the colon followed by dissection of the bowel together
with blood vessels and the accompanying mesocolon and
lymph nodes. In the case of rectal carcinoma, concomitant
total mesorectal excision and defunctioning loop ileostomy
were performed. For vessel sealing, we used either Ethicon
Harmonic ACE, Olympus THUNDERBEAT or Covidien
LigaSure (according to the surgeon’s preference). Greater
vessels were clipped with titanium clips. The specimen was
extracted via transverse minilaparotomy, which was pro-
tected with Applied Medical Alexis Wound Protector. The
continuity of the bowel was restored using a circular stapler
(left hemicolectomy, sigmoid resection, rectal resection) or
with extracorporeal or intracoproperal side-to-side anasto-
mosis (right hemicolectomy). Neither nasogastric tubes nor
drains were used routinely. Finally, bilateral transversus
abdominisplane block (TAP block) under ultrasound guid-
ance was used at the end of the surgery (20 mL of 0.25%
bupivacaine solution on each side).
Outcome measures
The patients were divided into two groups depending on
the level of compliance with ERAS protocol (above or
below 80% compliance). Compliance was assessed simi-
larly to Gustafsson et al. [11], including elements that were
primarily decided by the staff and delivered before and
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Excluded (n=23)
• Primary open surgery (n=5)
• Emergency cases (n=11)
• TEM removal (n=7) 
-
Laparoscopic procedure (n=404)
Excluded (n=54)
♦ Multivisceral resection (n=10)
♦ Concomitant inflammatory bowel diseases (n=3)
♦ Intensive care unit stay (n=3)
♦ Stage IV according to AJCC classification (n=31)
♦ Lost in follow up (n=7)
Patients included in the analysis
(n=350)
Assessed for eligibility (n=427)
Fig. 1 Patients flow through the
study
Table 1 ERAS protocol used in our department
1. Preoperative counselling and patient‘s education
2. No bowel preparation (oral bowel preparation in the case of low rectal resection with TME and defunctioning loop ileostomy) plus oral
neomycin 3 9 4 g and Metronidazole 3 9 500 mg on the day before surgery)
3. Preoperative carbohydrate loading (400 ml of Nutricia preOp 2 h prior surgery)
4. Antithrombotic prophylaxis (Clexane 40 mg sc. starting in the evening prior surgery)
5. Antibiotic prophylaxis (preoperative cefuroxime 1,5 g ? metronidazole 0,5 g iv 30–60 min. prior surgery)
6. Laparoscopic surgery
7. Balanced intravenous fluid therapy (\ 2500 mL intravenous fluids during the day of surgery, less than 150 mmol sodium)
8. No nasogastric tubes postoperatively
9. No drains left routinely for colonic resections, one drain placed for\ 24 h in case of TME
10. TAP block and standard anesthesia protocol
11. Urinary catheter removal on the first postoperative day
12. Prevention of postoperative nausea and vomiting (PONV) (dexamethasone 8 mg iv., ondansetron 8 mg iv., metoclopramide 10 mg iv.)
13. Postoperative oxygenation therapy (4–6 l/min.)
14. Early oral feeding (oral nutritional supplement 4 h postoperatively—Nutrcia Nutridrink or Nestlé Impact, light hospital diet and oral
nutritional supplements on the first postoperative day, full hospital diet in the second postoperative day)
15. Avoiding opioids, multimodal analgesia (oral when possible—paracetamol 4 9 1 g, ibuprofen 2 9 200 mg, metamizole 2 9 500 mg, or
ketoprofen 2 9 100 mg)
16. Full mobilization on the first postoperative day (getting out of bed, going to toilette, walking along the corridor, at least 4 h out of bed)
Compliance was calculated from elements 1–13 (items of which implementation was depending on the medical staff). Elements 14–16 are
convalescence parameters
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during the day of surgery. It was calculated as the number
of interventions fulfilled/13*100% (total number of pre-
operative, intra and early postoperative interventions).
These elements were chosen because their use was mainly
dependent on the medical staff. Postoperative compliance
is also influenced by the previous treatments and can, to a
large extent, be regarded as outcomes. For this reason, they
were not included in the calculation.
The primary outcome was overall 3-year survival. The
secondary outcomes were postoperative complications,
length of hospital stay and recovery parameters.
Statistical analysis
All data were analyzed with Statsoft STATISTICA v.13
(StatSoft Inc., Tulsa, OK, USA). The results are presented
as mean ± standard deviation (SD), median and
interquartile range (IQR), and hazard ratio (HR) with 95%
confidence intervals (CI) when appropriate. The study of
categorical variables used the Chi-square test of indepen-
dence. The Shapiro–Wilk test was used to check for normal
distribution of data, and Student’s t test was used for nor-
mally distributed quantitative data. For non-normally dis-
tributed quantitative variables, the Mann–Whitney U test
was used. For the purposes of further analysis, the entire
group of patients was divided into subgroups depending on
compliance with the ERAS protocol (\ 80% and C 80%).
This was the target compliance with the ERAS protocol in
our department [18]. Survival data were analyzed accord-
ing to the Kaplan–Meier method. The log-rank test was
used to detect differences between groups. Univariate and
multivariate analysis was performed using Cox propor-
tional hazards. The variables from p\ 0.05 have been
included in the model. Results were considered statistically
significant when the p value was found to be less than 0.05.
Ethical approval
The study was approved by the local ethics review com-
mittee (approval number 1072.6120.225.2017). All proce-
dures have been performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki
and its later amendments.
Results
Characteristics of the study group
During the study period, 427 patients with colorectal can-
cer were treated in our department. Figure 1 shows the
patients’ flow through the study and the reasons for
exclusion. In total, 350 patients were enrolled for further
analysis (181 males, 169 females). The mean age was
64.4 years (19–94 years). The demographic analysis of the
group is shown in Table 2.
Group 1 included 109 patients and Group 2 included 241
patients. There were no statistically significant differences
between groups for the demographic parameters sex, age,
BMI, ASA scale, and comorbidities. The groups were also
comparable in terms of location and characteristics of their
tumor/s (Table 2).
A subgroup analysis demonstrated that[ 80% compli-
ance with ERAS protocol was associated with better sur-
vival among patients with colorectal cancer (Fig. 2). The
median time of follow-up was 35 months (mean
35.6 months, range 12–60 months). Three patients died
within 30 days after surgery in ICU care, because of res-
piratory failure in two cases (as a result of pneumonia) and
anastomotic leakage in one case.
A univariate analysis of overall survival (Table 3)
showed that age C 65 years (HR 3.33, 95% CI 1.32–8.23,
p = 0.0037), ASA scale III–IV (HR 3.92, 95% CI
1.91–7.74, p = 0.0006), cardiovascular disease (HR 3.28,
95% CI 1.52–7.44, p = 0.0009), renal disease (HR 2.96,
95% CI 1.13–7.74, p = 0.0269), AJCC stage III (HR 2.86,
95% CI 1.44–5.81, p = 0.0031), postoperative complica-
tions (HR 2.46, 95% CI 1.22–4.76, p = 0.0133), and\
80% compliance with the ERAS protocol (HR 4.51, 95%
CI 3.29–21.21, p = 0.0018) were predictors for poor
prognosis.
The Cox proportional model showed that only AJCC III
(HR 3.28, 95% CI 1.61–6.59, p = 0.0021), postoperative
complications (HR 2.63, 95% CI 1.19–5.52, p = 0.0161),
and\ 80% compliance with ERAS protocol (HR 3.38,
95% CI 2.23–5.21, p = 0.0102) were independent predic-
tors for poor prognosis and shorter survival.
According to the Kaplan–Meier curves, 3-year overall
survival was 88% in Group 2 and 76% in Group 1. The risk
of death 3 years after surgery was lowered by 56%, HR
0.44 (0.21–0.91) in Group 2 compared to Group 1.
There were statistically significant differences in short-
term outcomes between groups. There were more compli-
cations in Group 1 compared to Group 2 (44% vs. 23.2%,
p\ 0.0001), without a difference in severity according to
the Clavien–Dindo classification (p = 0.6277). Median
length of stay (LOS) was significantly lower in Group 2 (6
vs. 4 days, p\ 0.0001). Readmission rate was comparable
in both groups (9.2% vs. 9.1%, p = 0.9999), respectively.
Functional recovery was also improved with better com-
pliance. Both tolerance of an oral diet on the first postop-
erative day (53.2% vs. 81.3%, p\ 0.0001) and
mobilization of a patient on the day of surgery (78% vs.
96.3%, p\ 0.0001) was better in Group 2. The percentage
of patients who did not require administration of opioid
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drugs was not statistically significant between groups
(51.4% vs. 40.2%, p = 0.052). Short-term outcomes are
presented in Table 4.
Discussion
The novel finding in this study is that compliance with the
ERAS protocol was an independent predictor of improved
3-year survival after laparoscopic colorectal resections.
The 3-year risk of death was more than three times higher
in patients with compliance\ 80%. In addition, other
well-known predictors of poorer survival rates also influ-
enced survival, including postoperative complications and
stage III of colorectal cancer. There were no differences in
study groups in terms of baseline demographic
characteristics, ASA score and stage of cancer, nor for the
use adjuvant chemotherapy.
ERAS protocols in elective colorectal surgery have been
widely accepted, and the evidence behind the benefits and
safety of ERAS has repeatedly been shown [11, 18, 19].
The adoption of ERAS principles is increasing due to
significantly better short-term outcomes, but less is known
about what ERAS can bring to long-term outcomes. Large
database studies have shown an association between post-
operative complications and reduced long-term survival
after major surgery[15]. Similar findings were recently
reported for open colorectal cancer surgery in ERAS-
managed care [11, 15]: Improved compliance with the
ERAS protocol was associated with the improved short-
term benefits of fewer postoperative complications, which
in turn was associated with a 42% reduction in 5-year
Table 2 Demographic analysis of patient groups
Parameter Group 1\ 80% Group 2 C 80% p value
Number of patients, n 109 241 –
Females, n (%) 54 (49.5%) 113 (46.9%) 0. 6454
Males, n (%) 55 (50.5%) 128 (53.1%)
Mean age, years ± SD 64.9 ± 14.3 63.8 ± 13.9 0.3291
BMI, kg/m2 ± SD 26.1 ± 4.2 26.7 ± 5.2 0.3405
ASA 1, n (%) 6 (5.5%) 9 (3.7%) 0. 5739
ASA 2, n (%) 61 (56%) 153 (63.6%)
ASA 3, n (%) 39 (35.8%) 74 (30.7%)
ASA 4, n (%) 3 (2.7%) 5 (2%)
Any comorbidity, n (%) 75 (68.8%) 158 (65.6%) 0. 5510
Cardiovascular, n (%) 40 (36.7%) 81 (33.6%) 0. 5739
Hypertension, n (%) 53 (48.6%) 119 (49.4%) 0. 8961
Diabetes, n (%) 23 (21.1%) 38 (15.8%) 0. 2232
Pulmonary disease, n (%) 11 (10.1%) 20 (8.3%) 0. 5846
Renal disease, n (%) 8 (7.3%) 14 (5.8%) 0. 5849
Formation of stoma 23 (21.1%) 66 (27.4%) 0. 2112
Median operative time, min. (IQR) 180 (140–240) 190 (160–230) 0.7148
Median intraoperative blood loss, mL (IQR) 100 (50–100) 100 (50–150) 0.7797
Conversion, n (%) 5 (4.6%) 7 (2.9%) 0. 4231
Need for blood transfusion, n (%) 9 (8.3%) 21 (8.7%) 0.8876
Colon, n (%) 71 (65.1%) 155 (64.3%) 0.8816
Rectum, n (%) 38 (34.9%) 86 (35.7%)
Neoadjuvant treatment, n (%) 19 (17.4%) 59 (24.5%) 0. 1422
Adjuvant chemotherapy, n (%) 37 (33.9%) 62 (25.7%) 0. 1139
AJCC stage I, n (%) 40 (36.7%) 101 (41.9%) 0.6425
AJCC stage II, n (%) 36 (33.0%) 75 (31.1%)
AJCC stage III, n (%) 33 (30.3%) 65 (27.0%)
Tumor grade G1, n (%) 11 (16.0%) 27 (17.1%) 0. 5287
Tumor grade G2, n (%) 49 (71.0%) 118 (74.7%)
Tumor grade G3, n (%) 9 (13.0%) 13 (8.2%)
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mortality. Our study is one of the first focusing on patients
operated only with laparoscopic technique. This allowed us
to achieve a homogenous group of patients.
There are several potential explanations why better
compliance with ERAS protocols contributed to improved
survival. Firstly, it has been shown that improved adher-
ence to the protocol leads to not only shorter recovery but
also lowers postoperative complication rates [14]. This was
also the case in the present study, as were return of key
functions which resulted in shorter length of postoperative
stay. Previous studies have confirmed that the occurrence
of postoperative complications has a great impact on long-
term outcomes [15, 20]. This could be the result of either
delayed adjuvant treatment or no adjuvant treatment at all
in complicated cases. An analysis of Merkow et al. showed
that only 70% of uncomplicated stage III cancer patients
receive postoperative chemotherapy, and this rate drops
dramatically when major postoperative complications
occur [21]. This factor, together with prolonged length of
stay and readmission, has been also confirmed by Malietzis
in a meta-analysis of 15 studies [22]. Moreover, Tevis et al.
observed that even though adjuvant treatment is adminis-
tered within the window of opportunity, patients suffering
from postoperative complications still had a poorer prog-
nosis [23]. Other factors than the delay in starting post-
operative chemotherapy may also contribute to
postoperative survival. Less stress during uncomplicated
surgery may improve the function of the immune system,
and this in turn may enhance the resistance to relapsing
cancer and manage any remaining cancer cells [24]. In the
present study, both adherence to ERAS protocol and
development complications were independent risk factors
for the multivariate analyses, which suggest they both
contribute to the outcomes. Our results are in line with
Gustafsson et al. who confirmed the association between
increased adherence to the ERAS protocol and improved
colorectal cancer-specific 5-year survival. It seems that our
Fig. 2 Kaplan–Meier curves of overall survival according to
compliance with ERAS protocol. Patients who had[ 80% compli-
ance with ERAS protocol showed significantly improved survival
rates compared with patients with less than 80%, p = 0.0007 (Log-
rank test for equality of survival functions)
Table 3 Univariate analysis of overall survival
Parameter HR (95% CI) p value
Sex (female vs. male) 0.87 (0.42–1.81) 0.7411
Age (\ 65 vs. C 65 years) 3.33 (1.32–8.23) 0.0037
BMI (\ 25 vs. C 25 kg/2) 1.44 (0.69–2.99) 0.3264
ASA scale (I–II vs. III–IV) 3.92 (1.91–7.74) 0.0006
Neoadjuvant treatment (yes vs. no) 0.32 (0.07–1.33) 0.1184
Cardiovascular disease (no vs. yes) 3.28 (1.52–7.44) 0.0009
Hypertension (no vs. yes) 1.16 (0.56–2.39) 0.6826
Diabetes (no vs. yes) 1.55 (0.69–3.47) 0.2907
Pulmonary disease (no vs. yes) 2.09 (0.86–5.13) 0.1045
Renal disease (no vs. yes) 2.96 (1.13–7.74) 0.0269
Tumor location (rectum vs. colon) 0.61 (0.13–2.91) 0.5122
AJCC (I–II vs. III) 2.86 (1.44–5.81) 0.0031
Time of the surgery (\ 200 vs.[ 200 min.) 2.02 (0.97–4.99) 0.0501
Intraoperative blood loss (\ 200 vs.[ 200 mL) 1.11 (0.42–2.687) 0.8491
Postoperative complications (no vs. yes) 2.46 (1.22–4.76) 0.0133
Compliance with ERAS protocol (C 80% vs.\ 80%) 4.51 (3.29–21.21) 0.0018
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results are comparable when looking at their Kaplan–Meier
survival estimates, although we set different cutoff values
of adherence (70% vs. 80%).
We also confirmed that better compliance to the ERAS
protocol results in better short-term results. This not only
shortens LOS and enhances convalescence, but also redu-
ces the morbidity rates. This has been previously studied
elsewhere [6, 11, 14, 18]. Subsequently, an extensive sys-
tematic review by Messenger et al. of 34 studies containing
10,861 laparoscopic resections identified protocol compli-
ance as the most frequently reported and most influential
predictive factor for outcomes of ERAS perioperative care
following laparoscopic colorectal resection [25].
A key mechanism of ERAS protocols improving post-
operative outcomes is stress minimization and the reduc-
tion in insulin resistance [26–28]. ERAS impacts immune
function by minimizing the inflammatory responses, and
this may affect long-term survival after cancer surgery. A
better-preserved immune competence, which includes
specific HLA-DR immune response, might protect against
potential consequences of dissemination of cancer cells and
in consequence distant metastases [29–31]. Minimally
invasive techniques also reduce this aspect of the stress
response [32–34]. Moreover, the philosophy of ERAS
involved many aspects of perioperative care. It is believed
and often shown that its success lays rather in the aggre-
gation of marginal gains and multimodal approach rather
than in one particular element [14, 35].
There are limitations of our study. To assess survival,
we used the national personal identification number data-
base (PESEL) which allows for determination of the date
of death but does not provide information on cancer-
specific death. The compliance of ERAS protocol in our
group was not equal throughout the whole study and was
lower at the early stages [10, 14]. Additionally, we lack
detailed data of the adjuvant treatment because a significant
proportion of patients were treated outside our oncology
department, and therefore, we were not able to confirm
which chemotherapy had been administered. We also
decided to include 13 elements rather than all 16 for
compliance analysis. The way we studied compliance was
to investigate the adherence to items that are subject to
staff decisions (pre- and intraoperatively), leaving aside
postoperative elements that depend on compliance levels in
the earlier phases as was shown in our results and reported
elsewhere (11, should also be available in most other short-
term studies).. This way of compliance calculations has
been previously used in other studies[11]. All our patients
are actively encouraged to get out of bed, start eating and
drinking (meaning that in terms of implementation of these
items we would get 100% compliance to these items).
However, not all of them are getting out of bed and tol-
erating oral diet in part due to poor compliance in the
earlier phases.
Conclusions
This study reports an association between adherence to the
ERAS Society Guidelines and long-term survival after
laparoscopic colorectal resection for non-metastatic cancer.
Lower adherence to the protocol, together with stage of
cancer and postoperative complications, was an indepen-
dent risk factor for poorer 3-year survival rates. Due to the
lack of data about disease-specific survival and type of
adjuvant treatment, our study requires confirmation via
other similar analyses. Nevertheless, the findings suggest
Table 4 Short-term outcomes in analyzed groups
Parameter Group 1\ 80% Group 2 C 80% p value
Tolerating oral diet on the first postoperative day, n (%) 58 (53.2%) 196 (81.3%) \ 0.0001
Mobilization on the first postoperative day, n (%) 85 (78.0%) 232 (96.3%) \ 0.0001
No postoperative use of opioids, n (%) 56 (51.4%) 97 (40.2%) 0.0520
Time to first flatus, days ± SD 2.32 ± 1.53 1.90 ± 2.05 0.0040
Patients without complications, n (%) 61 (56.0%) 185 (76.8%) \ 0.0001
Patients with complications, n (%) 48 (44.0%) 56 (23.2%)
Clavien–Dindo 1, n (%) 22 (45.8%) 25 (44.6%) 0.6277
Clavien–Dindo 2, n (%) 9 (18.8%) 16 (28.6%)
Clavien–Dindo 3, n (%) 12 (25.0%) 11 (19.6%)
Clavien–Dindo 4, n (%) 4 (8.3%) 2 (3.6%)
Clavien–Dindo 5, n (%) 1 (2.1%) 2 (3.6%)
Mean length of hospital stay, days ± SD 8.11 ± 8.23 5.48 ± 6.76 \ 0.0001
Median length of hospital stay, days (IQR) 6 (4–8) 4 (3–6)
Readmission, n (%) 10 (9.2%) 22 (9.1%) 0.9999
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that ERAS brings benefits in oncologic surgery beyond the
early postoperative period.
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